The Role of PDTs in Clinical Practice
Panelists discuss the current use of prescription digital therapeutics (PDTs) in clinical practice, highlighting their potential in treating mental health conditions.
While no PDTs are yet approved for schizophrenia, CT-155 shows promise in phase 3 trials. Existing PDTs, such as Rejoyn for depression, demonstrate the potential for technology-based interventions.
- PDTs are not yet approved for schizophrenia, but CT-155 has received breakthrough designation and completed phase 3 clinical trials.
- For patients with depression, clinicians can prescribe reSET, an approved digital therapeutic that provides cognitive behavioral therapy as an adjunct to medications.
Clinical experience with existing PDTs reveals both opportunities and challenges for patient care.
Author's summary: PDTs show promise in treating mental health conditions.